NYSE$MDT

Medtronic PLC · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Medtronic's Q1 2024 financial results were reported, showing broad strength across businesses and geographies, resulting in mid-single digit revenue growth.

Medtronic reported a solid start to fiscal year 2024, with revenue of $7.7 billion, a 4.5% increase as reported and 6.0% organic. GAAP EPS was $0.59, a 16% decrease, while non-GAAP EPS was $1.20, a 6% increase. The company has raised its FY24 organic revenue growth and EPS guidance.

  • Revenue of $7.7 billion increased 4.5% as reported and 6.0% organic.
  • GAAP diluted earnings per share (EPS) of $0.59 decreased 16%; non-GAAP diluted EPS of $1.20 increased 6%.
  • Company increases FY24 organic revenue growth and EPS guidance.
  • Commenced U.S. launches of the MiniMed™ 780G system with Guardian™ 4 sensor in Diabetes and the Micra™ AV2 and Micra™ VR2 leadless pacemakers in Cardiovascular.

Headline financials

Total Revenue

$7.7B

Previous: $7.37B+4.5%
EPS (adj)

$1.20

Previous: $1.13+6.2%
Organic Revenue Growth

6.0%

Previous: -4.0%+250.0%
Capital Expenditures

-$354M

Previous: -$426M+16.9%
Free Cash Flow

$521M

Previous: $657M-20.7%
Net Income

$791M

Previous: $929M-14.9%
Operating Income

$1.27B

Previous: $1.13B+12.7%
Gross Profit

$5.07B

Previous: $4.86B+4.5%
Cash & Equivalents

$1.34B

Previous: $2.14B-37.4%
Total Assets

$90.8B

Previous: $89.9B+1.0%
Stock-Based Comp

$73M

Previous: $62M+17.7%

Revenue & EPS history

Medtronic · Revenue · Quarterly

$7.7B

Q1 2024+4.5%vs Q1 2023
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Medtronic · $7.7B total across 10 segments · Q1 2024

  • Surgical & Endoscopy
    $1.55B+15.5%
  • Cardiac Rhythm & Heart Failure
    $1.45B+3.8%
  • Cranial & Spinal Technologies
    $1.1B+5.8%
  • Structural Heart & Aortic
    $814M+9.9%
  • Specialty Therapies
    $695M+4.2%
  • Coronary & Peripheral Vascular
    $589M+1.7%
  • Diabetes
    $578M+6.8%
  • Acute Care & Monitoring
    $493M
  • Neuromodulation
    $420M+3.7%
  • Other
    $16M-97.6%

Forward guidance

The company raised its FY24 organic revenue growth guidance to 4.5% versus the prior range of 4.0% to 4.5%. The company increased its FY24 diluted non-GAAP EPS guidance from the prior range of $5.00 to $5.10 to the new range of $5.08 to $5.16.

Tailwinds

  • Revenue outperformance
  • Focus on expense management
  • Operating margin expansion
  • Mid-single digit adjusted earnings growth
  • Improved fundamentals

Headwinds

  • Impact of foreign currency
  • Revenue related to certain businesses reported as Other
  • Uncertainty of potential charges or gains
  • Difficult to predict the timing of recognition of potential charges or gains
  • Such items could have a substantial impact on GAAP measures of financial performance.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-0.2%

Avg return

Earnings day

-0.0%

Avg return

5 days after

-1.4%

Avg return

30 days after

57%

37 / 65 earnings

Positive

+6.2%

Q1 2019

Best reaction

-7.3%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-2.8%-2.6%-12.7%
Q2 2026+3.9%+5.1%+2.3%
Q1 2026-3.1%-0.1%+3.0%
Q4 2025-2.2%-6.6%-0.0%
Q3 2025-7.3%-3.1%-1.7%
Q2 2025-4.0%-1.6%-8.7%
Q1 2025+3.2%+4.2%+5.5%
Q4 2024-4.0%-4.4%-4.8%
Q3 2024+1.8%+1.5%-1.2%
Q2 2024+4.3%+5.1%+9.0%
Q1 2024+2.5%+0.7%-1.4%
Q4 2023-6.9%-5.7%-0.0%
Q3 2023+0.4%-1.5%-8.5%
Q2 2023-4.0%-3.9%-6.3%
Q1 2023-4.1%-3.9%-10.2%
Q4 2022-6.1%-5.1%-14.5%
Q3 2022+2.4%+5.2%+5.7%
Q2 2022-2.1%-5.0%-12.0%
Q1 2022+4.7%+4.1%+1.7%
Q4 2021+0.3%-0.8%+2.8%
Q3 2021+2.6%+1.1%+0.7%
Q2 2021+2.1%+3.3%+2.8%
Q1 2021+3.9%+7.7%+1.1%
Q4 2020-3.4%-0.9%-4.3%
Q3 2020-3.0%-3.5%-32.5%
Q2 2020+0.5%-0.4%+2.0%
Q1 2020+3.5%+1.8%+6.6%
Q4 2019+4.8%+2.9%+12.0%
Q3 2019+0.6%+1.6%-0.2%
Q2 2019+2.9%+1.8%-0.5%
Q1 2019+6.2%+6.1%+8.3%
Q4 2018+1.2%+0.2%+1.8%
Q3 2018-3.1%-3.5%-6.2%
Q2 2018+4.4%+5.5%+3.3%
Q1 2018-4.5%-5.3%-4.8%
Q4 2017+0.5%+0.2%+5.3%
Q3 2017+0.9%+2.7%+2.5%
Q2 2017-6.0%-6.3%-11.0%
Q1 2017-0.1%+0.2%+1.2%
Q4 2016-1.4%+1.5%+6.2%
Q3 2016-3.6%
Q2 2016+2.7%
Q1 2016-3.6%
Q4 2015+0.2%
Q3 2015+4.3%
Q2 2015+3.7%
Q1 2015+1.1%
Q4 2014-1.0%
Q3 2014-1.2%
Q2 2014-2.4%
Q1 2014-2.6%
Q4 2013+3.3%
Q3 2013-5.0%
Q2 2013+1.6%
Q1 2013+1.2%
Q4 2012+2.1%
Q3 2012+2.0%
Q2 2012-6.5%
Q1 2012-3.2%
Q4 2011+1.5%
Q3 2011+1.4%
Q2 2010-0.2%
Q1 2010+1.5%
Q4 2010+0.7%
Q3 2009+0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro